Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Parathyroidectomy effective for primary hyperparathyroidism regardless of localization technique
Parathyroidectomy yields excellent surgical outcomes in patients with primary hyperparathyroidism (PHPT), whether or not intraoperative localization technique (IOLT) or intraoperative parathyroid hormone (IOPTH) monitoring have been used, reports a recent study.
Parathyroidectomy effective for primary hyperparathyroidism regardless of localization technique
29 Jul 2022
Glycated albumin offers clues to mortality risk even in nondiabetic individuals
Elevated levels of glycated albumin appear to indicate a greater risk of all-cause and cardiovascular mortality among adults, regardless of their diabetes status, according to a study.
Glycated albumin offers clues to mortality risk even in nondiabetic individuals
29 Jul 2022
Neutrophils release more cytokines in DM, HFpEF patients
In patients with type 2 diabetes mellitus (DM) or heart failure with preserved ejection fraction (HFpEF), neutrophils seem to secrete more cytokines, contributing to low-grade chronic inflammation, a recent study reports.
Neutrophils release more cytokines in DM, HFpEF patients
27 Jul 2022
Growth hormone reduces liver fat, fibro-inflammation in obese/overweight adults with NAFLD
In adults with overweight/obesity and nonalcoholic fatty liver disease (NAFLD), daily administration of growth hormone (GH) reduced hepatic steatosis and improved markers of hepatic inflammation and fibrosis, a study has shown.
Growth hormone reduces liver fat, fibro-inflammation in obese/overweight adults with NAFLD
27 Jul 2022
Abdominal aortic calcification linked to CAD, CI in T2DM
In patients with type 2 diabetes mellitus (T2DM), abdominal aortic calcification might be an important indicator of coronary artery disease (CAD) and cerebral infarction (CI), a new study has found.
Abdominal aortic calcification linked to CAD, CI in T2DM
26 Jul 2022
Empagliflozin shows promise for chronic SIAD-induced hyponatremia
The sodium-glucose cotransporter 2 inhibitor empagliflozin showed potential as a treatment alternative for hyponatremia due to chronic syndrome of inadequate antidiuresis (SIAD), according to a trial presented at ENDO 2022.
Empagliflozin shows promise for chronic SIAD-induced hyponatremia
26 Jul 2022
Obese/overweight patients incur 10 percent long-term weight loss with lifestyle management, medication
Individuals who are overweight or obese can achieve an approximately 10 percent weight loss over 3–5 years with the use of anti-obesity medications in addition to lifestyle management, according to a retrospective study presented at ENDO 2022.